One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation.
Alendronate, an anti-remodeling agent, is commonly used to treat patients suffering from osteoporosis by increasing bone mineral density. Though fracture risk is lowered, an increase in microdamage accumulation has been documented in patients receiving alendronate, leading to questions about the potentially detrimental effects of remodeling suppression on the local tissue (material) properties. In this study, trabecular bone cores from the distal femur of beagle dogs treated for one year with alendronate, at doses scaled by weight to approximate osteoporotic and Paget's disease treatment doses in humans, were subjected to uniaxial compression to induce microdamage. Tissue level von Mises stresses were computed for alendronate-treated and non-treated controls using finite element analysis and correlated to microdamage morphology. Using a modified version of the Moore and Gibson classification for damage morphology, we determined that the von Mises stress for trabeculae exhibiting severe and linear microcrack patterns was decreased by approximately 25% in samples treated with alendronate compared with non-treated controls (p<0.01), whereas there was no reduction in the von Mises stress state for diffuse microdamage formation. Furthermore, an examination of the architectural and structural characteristics of damaged trabeculae demonstrated that severely damaged trabeculae were thinner, more aligned with the loading axis, and less mineralized than undamaged trabeculae in alendronate-treated samples (p<0.01). Similar relationships with damage morphology were found only with trabecular orientation in vehicle-treated control dogs. These results indicate that changes in bone's architecture and matrix properties associated with one year of alendronate administration reduce trabecular bone's ability to resist the formation of loading-induced severe and linear microcracks, both of which dissipate less energy prior to fracture than does diffuse damage.
O'Neal
Jessica M
JM
Parker H. Petit Institute for Bioengineering and Bioscience and George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Diab
Tamim
T
Allen
Matthew R
MR
Vidakovic
Brani
B
Burr
David B
DB
Guldberg
Robert E
RE
D019386:Alendronate / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology*; D002113:Calcification, Physiologic / Q000187:drug effects; D004285:Dogs; D005260:Female; D020342:Finite Element Analysis; D005453:Fluorescence; D050723:Fractures, Bone / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D015775:Fractures, Stress / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology; D013997:Time Factors
D019386:Alendronate